Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited has disclosed a significant change in director Peter Laurence Molloy’s interests, reflecting an acquisition of 500,000 ordinary fully paid shares through an on-market trade, valued at $28,437.74. Following the transaction, the indirect interest held via Christine Louise Molloy and Aquarico Pty Ltd has increased to 1,030,000 shares, maintaining their substantial stake in the company.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
